Correlations between skin lesions induced by anti-tumor necrosis factor-α and selected cytokines in Crohn's disease patients

World Journal of Gastroenterology

Volumn 20, Issue 22, 2014, Pages 7019-7026

  Włodarczyk, Marcin ^a   Sobolewska, Aleksandra ^a   Wójcik, Bartosz ^a   Loga, Karolina ^a   Fichna, Jakub ^a   Wiśniewska Jarosińska, Maria ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Biological therapy; Crohn's disease; Interferon ; Interleukin 17A; Interleukin 23; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB; GAMMA INTERFERON; HEMOGLOBIN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; CYTOKINE; GASTROINTESTINAL AGENT; IFNG PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACNE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DRY SKIN; ECZEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FOLLOW UP; FURUNCULOSIS; HEMATOCRIT; HUMAN; MALE; PROSPECTIVE STUDY; PSORIASIS; SKIN DEFECT; SKIN MANIFESTATION; THROMBOCYTE; ANTAGONISTS AND INHIBITORS; BLOOD; CASE CONTROL STUDY; DRUG EFFECTS; DRUG ERUPTIONS; IMMUNOLOGY; PATHOLOGY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SKIN; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; CROHN DISEASE; CYTOKINES; DRUG ERUPTIONS; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-23; MALE; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84902203655     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i22.7019     Document Type: Article

References (22)

1. Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, Kupcinskas L, Mantzaris G, Travis S, Stange E. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27 [PMID: 21122488 DOI: 10.1016/ j.crohns.2009]
2. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, Danese S, D'Hoore A, Gassull M, Gomollón F, Hommes DW, Michetti P, O'Morain C, Oresland T, Windsor A, Stange EF, Travis SP. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management. J Crohns Colitis 2010; 4: 28-62 [PMID: 21122489]
3. Hovhannisyan Z, Treatman J, Littman DR, Mayer L. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology 2011; 140: 957-965 [PMID: 21147109 DOI: 10.1053/j.gastro]
4. Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos PL. Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. World J Gastroenterol 2003; 9: 2300-2307 [PMID: 14562397]
5. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig Liver Dis 2008; 40 Suppl 2: S253-S259 [PMID: 18598997 DOI: 10.1016/S1590-8658(08)60534-4]
6. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31. e1-31.15 [PMID: 17097378 DOI: 10.1016/j.jaad.2006.07.017]
7. Hyams JS. Inflammatory bowel disease. Pediatr Rev 2005; 26: 314-320 [PMID: 16140873 DOI: 10.1542/pir.26-9-314]
8. Ariza ME, Williams MV, Wong HK. Targeting IL-17 in psoriasis: from cutaneous immunobiology to clinical application. Clin Immunol 2013; 146: 131-139 [PMID: 23314273 DOI: 10.1016/j.clim.2012.12.004]
9. Moustou AE, Matekovits A, Dessinioti C, Antoniou C, Sfikakis PP, Stratigos AJ. Cutaneous side effects of anti-tumor necrosis factor biologic therapy: a clinical review. J Am Acad Dermatol 2009; 61: 486-504 [PMID: 19628303 DOI: 10.1016/ j.jaad.2008.10.060]
10. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008; 9: 1-14 [PMID: 18092839 DOI: 10.2165/00128 071-200809010-00001]
11. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007; 86: 242-251 [PMID: 17632266 DOI: 10.1097/MD.0b013e3181441a68]
12. Safrany E, Szabo M, Szell M, Kemeny L, Sumegi K, Melegh BI, Magyari L, Matyas P, Figler M, Weber A, Tulassay Z, Melegh B. Difference of interleukin-23 receptor gene haplotype variants in ulcerative colitis compared to Crohn's disease and psoriasis. Inflamm Res 2013; 62: 195-200 [PMID: 23093364 DOI: 10.1007/s00011-012-0566-z]
13. Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63: 567-577 [PMID: 23468464 DOI: 10.1136/gutjnl-2012-302853]
14. Cayatte C, Joyce-Shaikh B, Vega F, Boniface K, Grein J, Murphy E, Blumenschein WM, Chen S, Malinao MC, Basham B, Pierce RH, Bowman EP, McKenzie BS, Elson CO, Faubion WA, Malefyt Rde W, Kastelein RA, Cua D, McClanahan TK, Beaumont M. Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease. Clin Transl Gastroenterol 2012; 3: e10 [PMID: 23238132 DOI: 10.1038/ctg.2012.2]
15. Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol 2009; 160: 319-324 [PMID: 19016708 DOI: 10.1111/j.1365-2133.2008.08902.x]
16. Thareja S, Paghdal K, Lien MH, Fenske NA. Reticular erythematous mucinosis--a review. Int J Dermatol 2012; 51: 903-909 [PMID: 22788804 DOI: 10.1111/j.1365-4632.2011.05292.x]
17. Geremia A, Arancibia-Cárcamo CV, Fleming MP, Rust N, Singh B, Mortensen NJ, Travis SP, Powrie F. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med 2011; 208: 1127-1133 [PMID: 21576383 DOI: 10.1084/jem.20101712]
18. Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol 2012; 7: 385-422 [PMID: 22054142 DOI: 10.1146/annurev-pathol-011811-132448]
19. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007; 25: 535-546 [PMID: 18021890 DOI: 10.1016/ j.clindermatol.2007.08.007]
20. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445: 648-651 [PMID: 17187052]
21. Denadai R, Teixeira FV, Saad-Hossne R. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended? Arq Gastroenterol 2012; 49: 172-176 [PMID: 22767007 DOI: 10.1590/S0004-28032012000200014]
22. Furuya Y, Ozeki T, Takayanagi R, Yokoyama H, Okuyama K, Yamada Y. Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease. Drug Metab Pharmacokinet 2007; 22: 20-25 [PMID: 17329907 DOI: 10.2133/ dmpk.22.20]